Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.


On Friday, French pharmaceutical firm Sanofi reduced its insulin price for uninsured patients in the US significantly. This comes as the Affordable Insulin Now Act has passed the House of Representatives, and a bi-partisan bill to cap costs is being introduced to the Senate.

Through Sanofi’s Insulins Valyou initiative, US diabetes patients without insurance but with a valid prescription will be able to get 30 days’ worth of one of the company’s insulin products for USD 35 – the exact price cap proposed by both bills.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs